Intensive chemotherapy of diffuse large b-cell lymphosarcoma in a female patient with chronic renal failure and afunctional left kidney

Full Text

Интенсивная химиотерапия диффузной в-крупноклеточной лимфосаркомы у больной с хронической почечной недостаточностью и афункциональной левой почкой. -

References

  1. Harris N. L., Jaffe Е. S., Diebold J. et al. World Health Organization classification diseases of the hematopoetic and lymphoid tissues: report of the clinical advisory committee meeting. - Airline House, Virginia, November 1997. J. Clin. Oncol. 1999; 17 (12): 3835-3849.
  2. Harris N. L., Jaffe E. S., Stein H. et al. A revised European-American classification of lymphoid neoplasm's: A proposal from The International Lymphoma Study Group. Blood 1994; 84 (5): 1301-1392.
  3. Воробьев А. И. (ред.) Руководство по гематологии. М.: Ньюдиамед; 2003; т. 2: 55, 98-100.
  4. Бабичева Л. Г., Поддубная И. В. Дополнительные клинико-лабораторные факторы прогноза при диффузной В-крупноклеточной лимфоме. Соврем. онкол. 2006; 8(1): 37-41.
  5. Abramson J. S., Shipp M. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood 2005; 106 (4): 1164-1174.
  6. Alizadeh A. A., Elsen M. В., Davis R. E. et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-511.
  7. Barrans S., Carter I., Morgan G. J. et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 2002; 99 (4): 1136-1142.
  8. Barrans S., Connor S., Evans P. et al. Rearrangement of the BCL-6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B-cell lymphoma. Br. J. Haematol. 2002; 117: 322-332.
  9. Barrans S., Evans P., Connor S. et al. The t(14; 18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome. Clin. Cancer Res. 2003; 9: 2133-2139.
  10. Rosenwald A., Wright G., Chan W. C. et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. N. Engl. J. Med. 2002; 346: 1937-1947.
  11. Shipp M. A., Ross K. N., Tramayo P. et al. Diffuse large B-cell lymphoma outcome prediction by gene expression profiling and supervised machine learning. Nat. Med. 2002; 8 (1): 68-74.
  12. Chung R., Lai R., Wei P. et al. Concordant but discordant bone marrow involvement in diffuse large B-cell lymphoma predicts a poor clinical outcome independent of the International Prognostic Index. Blood 2007; 110 (4): 1278-1282.
  13. Falini В., Fizzotti M., Pucciarini A. et al. A monoclonal antibody (MUM1) detects expression of the MUM1/IRF4 protein in a subset of germinal center В cells, plasma cells, and activated T cells. Blood 2000; 95: 2084-2092.
  14. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N. Engl. J. Med. 2005; 353: 1197-1205.
  15. Balzarotti M., Spina M., Sarina B. et al. Intensified CHOP regimen in aggressive lymphomas: maximal dose intensity and dose density of doxorubicin and cyclophosphamide. Ann. Oncol. 2002; 13 (9): 1341-1346.
  16. Brusamolino E., Rusconi C., Montalbetti L. et al. Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity. Haematologica 2006; 91: 496-502.
  17. Fisher R. Treatment of diffuse large B-cell lymphomas. Semin. Hematol. 2006; 34: 205.
  18. Coiffier В., Gisselbrecht C., Gaulard P. et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2 associated resistance to chemotherapy in elderly patients with diffuse large-B-cell lymphoma. Blood 2003; 6 (6): 1182.
  19. Магомедова А. У., Кравченко С. К., Кременецкая А. М. и др. Модифицированная программа NHL-BFM-90 в лечении больных диффузной В-крупноклеточной лимфосаркомой. Тер. арх. 2006; 10: 44-47.
  20. Pfreundschuh М., Trumper L., Osterborg A. et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large B-cell lymphoma: a randomized controlled trial by the MabThera International Trial (MinT) Group. Lancet Oncol. 2006; 7: 379-391.
  21. Freytes C., Loberiza F., Rizzo D. et al. Myeloablative allogenic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry. Blood 2004; 104 (12): 3797-3803.
  22. Gisselbrecht C., Lepage E., Molina T. et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J. Clin. Oncol. 2002; 20 (10): 2472-2479.

Statistics

Views

Abstract - 80

Cited-By


Article Metrics

Metrics Loading ...

Refbacks

  • There are currently no refbacks.

Copyright (c) 2020 Egorova E.K., Mar'in D.S., Shutova N.A., Galstian G.M., Savenko T.A., Kremenetskaia A.M., Kravchenko S.K., Magomedova A.U., Kovalenko A.V., Kaplanskaia I.B., Samoĭlova R.S., Kliasova G.A., Kozlova S.I.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:

 

© 2018 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies